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This meta-analysis of randomized controlled trials (RCTs) aims to investigate how to per-
form better interventions targeting modifiable risk factors of diabetic retinopathy (DR) to
prevent and control DR in patients with type 2 diabetes by comparing different intervention
types and follow-up intervals. Literature published before June 1st, 2019 were searched on
Pubmed, Embase and ScienceDirect. RCTs targeting modifiable risk factors of DR (including
blood glucose, blood pressure, lipid, dietary, physical activity and smoking) were selected
by two reviewers and double checked for accuracy. Random effects models were estimated
to calculate pooled Odds Ratios (OR). Twenty-two RCTs (n = 22,511) were included. In gen-
eral, interventions targeting modifiable risk factor of DR reduced the risk of developing DR
(I2 = 26.7%; OR = 0.60; 95% CI 0.45 to 0.79) and DR worsening (I2 = 0.0%; OR = 0.62; 95% CI 0.47
to 0.80; P < 0.001). Multifactorial interventions had better effect on reducing the risk of
development and progression of DR in comparison with other interventions, while only
blood-pressure-control interventions showed significant effect on slowing down DR wors-
ening. Additionally, interventions with follow-up >5 years had better effect on reduction of
DR development, and interventions with follow-up >2 years had better effect on reducing
the risk of DR worsening.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
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Diabetic retinopathy (DR), a microvascular complication of
diabetes, is the leading cause of preventable blindness in
working age population [1,2]. It is reported that after 20 years,
nearly all patients with type 1 diabetes and more than 60% of
those with type 2 diabetes will develop DR [3].
Studies have identified risk factors of DR development and
progression, such as duration of diabetes, hyperglycemia/gly-
cated hemoglobin value (HbA1c), hypertension, hyperlipi-
demia, pregnancy, nephropathy/renal disease, obesity,
smoking, moderate alcohol consumption and physical activ-
ity [1,3].
Several intervention studies aiming at identifying the
effect of intervention targeting modifiable risk factors of DR
among patients with type 2 diabetes have been conducted.
However, the results of these trials are not consistent in terms
of the effect of interventions on reducing the risk of develop-
ing DR and/or its worsening. For instance, with regard to the
interventions on hyperglycemia, the Veterans Affairs Dia-
betes Trial (VADT) found intensive glucose control had no sig-
nificant effect on preventing DR development but had
significant effect on slowing down its worsening [4,5], while
the Action in Diabetes and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation (ADVANCE) trial found
that intensive glucose control had no effect on delaying DR
progression (development or worsening) [6]. In the meantime,
another study conducted in Japan found that intensive glu-
cose control had significant effect on reducing the risk of both
development and worsening of DR [7]. With respect to inter-
ventions on hypertension, the Appropriate Blood Pressure
Control in Diabetes (ABCD) trail [8] found intensive blood
pressure control had no effect on preventing DR development,
but UK Prospective Diabetes Study (UKPDS) [9,10] found it to
be significantly effective. In addition, some trails have also
proven that interventions on multi-factors like blood glucose,
blood pressure, dietary, physical activity and smoking were
effective [11–13]. To date, no study has gathered all the evi-dence on different kinds of interventions targeting modifiable
risk factors of DR and compared their effects to find out how
to better perform interventions to prevent and control DR
among patients with type 2 diabetes.
This study aims to answer the following three questions by
carrying out a meta-analysis of randomized control trials
(RCTs).
First, could interventions targeting modifiable risk factors
of DR (blood glucose, blood pressure, lipid, dietary, physical
activity and smoking) reduce the risk of developing DR and/
or its worsening among patient with type 2 diabetes?
Second, among these interventions, what type of interven-
tion is most effective in reducing the risk of developing DR
and/or its worsening?
Third, how long should follow-up interval of interventions
be to better reduce the risk of developing DR and/or its
worsening?
2. Materials and methods
2.1. Data sources and searches
Pubmed, Embase and ScienceDirect were searched with
terms related to our study aim, including ‘‘prevention”, ‘‘in-
tervention”, ‘‘glycemic control”, ‘‘HbA1c”, ‘‘blood pressure
control”, ‘‘lipids”, ‘‘diet”, ‘‘physical activity”, ‘‘smoking”, ‘‘di-
abetic retinopathy”, ‘‘DR”, ‘‘type 2 diabetes”, ‘‘T2DM” and
other synonyms to identify articles related to our study
from January 1st, 1980 to June 1st, 2019. PubMed was
searched with MeSH terms and other synonyms in title/
abstract/keywords and 503 articles were identified. Embase
was searched with Emtree terms and other synonyms in
title/abstract/keywords and 1008 articles were identified.
ScienceDirect was searched with keywords in title/
abstract/keywords of research articles and 885 articles were
identified. After excluding duplicates, a total of 1991 articles
were identified, and details of the search syntax can be
found in the Supplementary Data.
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Eligible studies were screened from the 1991 articles based on
the inclusion and exclusion criteria below.
Inclusion criteria:
1. Studies with a randomized-controlled design presenting
original research
2. Study participants: patients with type 2 diabetes (If the
type of diabetes was unclear, the study was included if
the mean age of patients was over 30 because most of
these patients were likely to have type 2 diabetes.)
3. Studies that aimed to study the effect of interventions tar-
geting modifiable risk factors of DR (including blood glu-
cose, blood pressure, lipid, dietary, physical activity and
smoking) on the prevention and control of DR
4. Studies that provided data that could be used to calculate
Odds Ratio (OR) in order to evaluate the effect of interven-
tions targeting modifiable risk factors of DR on the preven-
tion and control of DR (e.g. The number of patients who
developed or did not develop DR in both intervention
group (IG) and control group (CG); the number of DR
patients whose condition worsened or did not worsen in
both groups; or other related data from which the useful
data could be derived)
Exclusion criteria:
1. Study participants: Patients under 18 years old
2. The intervention is medical treatment of DR rather than
just targeting modifiable risk factors of DR (e.g. drugs,
medical examinations, and surgeries)
3. Non-English publications
Of the 1991 articles, on the basis of the study titles and
abstracts, two reviewers (Yusufu and Zhang) excluded 1903
articles that: were not RCTs, were not original research (e.g.
reviews, secondhand-data analysis, and design studies), stud-
ied type 1 diabetes, gestational diabetes or other specific types
of diabetes, studied patients under 18 years old, did not study
the effect of interventions targeting modifiable risk factors of
DR on the prevention and/or control of DR, adopted medical
treatment of DR as interventions (e.g. drugs or medicines,
medical examinations, or surgeries), or were not published
in English. Two reviewers (Yusufu and Zhang) independently
examined the full-text of the remaining 88 articles. Among
those, 72 were excluded mainly due to lack of basic data that
would be needed to evaluate the effect of intervention on the
prevention and control of DR (Fig. 1). In case of disagreement,
the reviewers discussed with a third researcher (Sun) to reach
an agreement and all disagreements were resolved by con-
sensus. Finally, 16 articles [5–8,10–21] on 22 studies were
included in this meta-analysis.
2.3. Data extraction and quality assessment
Data from the 22 studies were extracted by two reviewers
(Yusufu and Zhang) with a standardized data extraction form.
The extraction form included: the name of the study (moststudies had an official name; if not, the study was named
after the first author), the year of publication, number of par-
ticipants, follow-up interval, the characteristics of partici-
pants (including data of IG and CG respectively, e.g. types of
patients, gender ratio, mean age, duration of diabetes, gly-
cated hemoglobin, blood pressure, total cholesterol, body
mass index and percentage of patients without DR at base-
line), study design and location, intervention methods, the
number of participants who developed or did not develop
DR in both IG and CG, and/or the number of DR patients
whose condition worsened or did not worsen in both groups,
and/or the number of participants with DR progression (For
studies failing to provide distinctive data on new onset and
worsening DR, the term ‘‘progression” was adopted to cover
both new onset and worsening DR). The details of each study
can be found in Supplementary Tables S1 and S2.
In all 22 studies, ophthalmologists diagnosed and/or evalu-
ated DR based on on-site ophthalmoscopy or report from the
primary care physicians. Most studies adopted the protocol
of the Early Treatment Diabetic Retinopathy Study (ETDRS)
to define the grade of DR and make diagnosis of DR [5–
8,10,14,18,19,21]. Some studies adopted the Wisconsin Epi-
demiologic Study of Diabetic Retinopathy [15,17], the EURO-
DIAB six-level grading [11,12,16], and other grading scales
[13,20] to define the grade of DR and make diagnosis of DR.
DR worsening was defined as a change of at least two steps
from baselinemeasurement in any eye [5,7,8,10,14]. One study
defined DR worsening based on an increase of at least one
level in any eye [11]. DR progression was defined as a change
of at least two or three steps from baseline measurement in
any eye [6,18,19,21]. Two studies defined DR progression as
an increase of at least one level in any eye [12,16]. The detailed
criteria used for the diagnosis, worsening and progression of
DR in each study can be found in Supplementary Table S3.
Some studies did not provide the needed data, in which
case, the data needed for the evaluation of the effect of inter-
ventions were obtained through calculation. One study only
provided the percentage of patients who developed DR at
follow-up in the IG and CG respectively [8]. We calculated
the number of patients with newly developed DR based on
the percentage and the number of patients. One study pro-
vided the number of patients without DR at baseline and
follow-up respectively in both IG and CG [15]. We subtracted
the number of patients without DR at follow-up from the
number of patients without DR at baseline to obtain the num-
ber of patients with newly developed DR. One study provided
the number of patients with DR at baseline and follow-up in
both IG and CG [13]. We subtracted the number of patients
with DR at baseline from the number of patients with DR at
follow-up to get the number of patients with newly developed
DR.
The interventions were classified into five categories based
on modifiable risk factors: (1) Blood-pressure-control inter-
vention, (2) Glycemic-control intervention, (3) Lipid-control
intervention, (4) Dietary-control intervention, and (5) Multi-
factorial intervention (interventions targeting more than
one risk factors).
We applied the Cochrane Collaboration’s tool to assess the
risk of bias in our study. This tool consists of six domains:
Fig. 1 – Flowchart of study selection.
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reporting bias and other bias. For each domain, the study was
graded as having a low risk, high risk, or unclear risk of bias
[22]. Grades of Recommendations Assessment, Development
and Evaluation (GRADE) was used to evaluate the level of evi-
dence in the meta-analysis with GRADEpro3.2. Two reviewers
(Yusufu and Zhang) assessed each study independently. Dis-
agreements between the reviewers were discussed with a
third researcher (Sun) in order to reach an agreement.
2.4. Data synthesis and analysis
The heterogeneity between the studies was evaluated with
the I2 test. Random effects models were estimated to calcu-
late pooled Odds Ratios (OR) of DR development, worsening
and progression. For these analyses we considered a value
of P < 0.05 to be significant. A sensitivity analysis was per-
formed to test the stability of the studies by excluding one
study at a time. Possible publication bias was assessed by esti-
mating funnel plots with Begg and Egger tests, and a value ofP < 0.1 was considered to be significant [23,24]. We followed
the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) checklist to report our meta-
analysis study [25]. All statistical analyses were performed
using Stata 11.0.
3. Results
3.1. Study selection and study characteristics
The 22 studies included in this meta-analysis studied a total
of 22,511 participants. The number of participants in each
study ranged from 35 [15] to 11,140 [6]. In most studies, the
number of males and females was similar [6–8,10–13,15–21],
but in two studies [5,14], over 90% of participants were male.
The follow-up interval of the interventions ranged from
1 year [15] to 8 years [21]. Blood-pressure-control intervention
was evaluated in 4 studies [8,9,19,21], glycemic-control inter-
vention was evaluated in 9 studies [5–7,14,15,18,19,21].
Lipid-control intervention was evaluated in 2 studies [19,21].
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Multifactorial intervention was evaluated in 5 studies
[11–13,16,17]. More details of the included studies can be
found in Supplementary Table S1.
3.2. Risk of bias
None of the RCTs included in this review were double-
blinded. In all studies, no high risk of bias was found in the
domains of selection bias, detection bias, attrition bias,
reporting bias, and other bias. More details of the risk of bias
could be found in Supplementary Table S4.
Quality of the evidence for most results on new onset DR
and DR worsening was moderate to high, except the results
of glycemic-control intervention (new onset DR), glycemic-
control intervention (DR Worsening), follow-up <2 years (DR
Worsening) and follow-up >5 years (DR Worsening) (The
details are presented in Supplementary Tables S5 and S6).
Quality of the evidence for most results on DR progression
was moderate to low (The details are presented in Supple-
mentary Table S7), which was mainly caused by the substan-
tial heterogeneity in this subgroup.
3.3. Results of intervention effects on DR prevention
A total of 11 studies from 10 articles provided data on the
number of patients with newly developed DR [5,7,8,10,11,13–
15,17,20]. In one article [20], there were two intervention
groups (Mediterranean diet supplemented with extra virgin
olive oil group and Mediterranean diet supplemented with
mixed nuts group) and one control group. Therefore, we
divided this study into two studies by matching the control
group with two intervention groups separately. Out of the 11
studies, 7 studies from 6 articles [7,10,11,13,17,20] revealed a
significant reduction in the number of newly developed DR
in intervention group compared with control group, and 4
studies from 4 articles [5,8,14,15] showed no effect.
Results on the effectiveness of all interventions targeting
modifiable risk factors of DR in reducing the risk of develop-
ing DR among patients with type 2 diabetes are presented in
Fig. 2. Heterogeneity between studies was small (I2 = 26.7%).
The pooled results indicated that interventions targeting
modifiable risk factor of DR reduced the risk of developing
DR among patients with type 2 diabetes significantly
(OR = 0.60; 95% CI 0.45 to 0.79; P < 0.001). The sensitivity of
the 11 studies was low, and the Begg and Egger tests did not
reveal publication bias. More details on the sensitivity analy-
sis and publication bias assessment can be found in Supple-
mentary Figs. S1 and S2.
Results of subgroup analyses on the effectiveness of differ-
ent types of interventions are presented in Fig. 2, Part A. There
was moderate heterogeneity among blood-pressure-control
intervention studies (I2 = 41.9%). Blood-pressure-control inter-
vention had no significant effect on reducing the risk of devel-
oping DR (OR = 0.68; 95% CI 0.41 to 1.14; P = 0.143). There was
moderate heterogeneity among glycemic-control interven-
tion studies (I2 = 38.2%). Glycemic-control intervention had
no significant effect on reducing the risk of developing DR
(OR = 0.70; 95% CI 0.31 to 1.57; P = 0.387). There was no hetero-
geneity between dietary-control intervention studies (I2 = 0%).Dietary-control intervention reduced the risk of developing
DR significantly (OR = 0.64; 95% CI 0.43 to 0.95; P = 0.025).
There was no heterogeneity among multifactorial interven-
tion studies (I2 = 0%). Multifactorial intervention reduced the
risk of developing DR significantly (OR = 0.27; 95% CI 0.14 to
0.53; P = <0.001).
Results of subgroup analyses on the effectiveness of differ-
ent follow-up intervals are presented in Fig. 2, Part B. There
was substantial heterogeneity among interventions with
follow-up < 2 years (I2 = 53.8%). Interventions with follow-
up < 2 years had no significant effect on reducing the risk of
developing DR (OR = 0.59; 95% CI 0.15 to 2.34; P = 0.452). There
was substantial heterogeneity among interventions with
follow-up of 2–5 years (I2 = 53.1%). Interventions with follow-
up of 2–5 years had no significant effect on reducing the risk
of developing DR (OR = 0.59; 95% CI 0.34 to 1.02; P = 0.060).
There was no heterogeneity among interventions with
follow-up over 5 years (I2 = 0%). Interventions with follow-up
of over 5 years reduced the risk of developing DR significantly
(OR = 0.57; 95% CI 0.42 to 0.78; P < 0.001).
3.4. Results of intervention effects on DR control
3.4.1. Effects on DR worsening
A total of 7 studies from 7 articles [5,7,8,10,11,14,15] provided
data on the number of patients suffering from worsening DR.
Out of the 7 studies, 4 studies from 4 articles [5,7,10,11] found
a significant effect on slowing the worsening of DR in inter-
vention group compared with control group, while the
remaining 3 studies from 3 articles [8,14,15] showed no effect.
Results on the effectiveness of all interventions targeting
modifiable risk factors of DR in reducing the risk of DR wors-
ening among patients with type 2 diabetes are presented in
Fig. 3. The pooled results showed that interventions targeting
modifiable risk factor of DR reduced the risk of DR worsening
in patients with type 2 diabetes significantly (OR = 0.62; 95% CI
0.47 to 0.80; P < 0.001). No heterogeneity between studies
(I2 = 0.0%) was found. The sensitivity of the 7 studies was
low, and the Begg and Egger tests did not reveal publication
bias. More details of sensitivity analysis and publication bias
assessment can be found in Supplementary Figs. S3 and S4.
Results of subgroup analyses on the effectiveness of differ-
ent types of interventions are presented in Fig. 3, Part A.
Blood-pressure-control intervention had significant effect on
slowing down the worsening of DR (OR = 0.52; 95% CI 0.34 to
0.78; P = 0.002) and no heterogeneity among blood-pressure-
control intervention studies was found (I2 = 0.0%). Glycemic-
control intervention reduced the risk of DR worsening, but
not significantly (OR = 0.71; 95% CI 0.50 to 1.00; P = 0.053),
and no heterogeneity among glycemic-control intervention
studies was found (I2 = 0.0%). There is no pooled results of
multifactorial intervention because there was only one study
in this subgroup.
Results of subgroup analyses on different follow-up inter-
vals are presented in Fig. 3, Part B. Interventions with follow-
up <2 years had no significant effect on reducing the risk of
DR worsening (OR = 0.91; 95% CI 0.40 to 2.09; P = 0.826), and
there was no heterogeneity (I2 = 0%). Interventions with
follow-up of 2–5 years reduced the risk of DR worsening sig-
nificantly (OR = 0.68; 95% CI 0.49 to 0.94; P = 0.020), and there
Fig. 2 – Forest plots for subgroup analysis on reducing the risk of developing diabetic retinopathy.
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of over 5 years had significant effect on reducing the risk ofDR worsening (OR = 0.41; 95% CI 0.24 to 0.69; P = 0.001) and
there was no heterogeneity (I2 = 0%).
Fig. 3 – Forest plot for subgroup analysis on reducing the risk of worsening diabetic retinopathy.
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A total of 10 studies from 6 articles [6,12,16,18,19,21] provided
data on the number of patients with DR progression. There
are two articles [19,21] each reporting the results on three
studies. Out of the 10 studies, 5 studies from 4 articles[12,16,19,21] found a significant reduction in the progression
of DR in intervention group compared with control group,
and 5 studies from 4 articles [6,18,19,21] showed no effect.
Results on the effectiveness of all interventions targeting
modifiable risk factors of DR in reducing the risk of DR pro-
Fig. 4 – Forest plot for subgroup analysis on reducing the risk of progression of diabetic retinopathy.
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Fig. 4. The pooled results revealed that interventions targeting
modifiable risk factor of DR reduced the risk of DR progression
among patients with type 2 diabetes significantly (OR = 0.74;
95% CI 0.59 to 0.92; P = 0.007). The overall heterogeneity
among studies was substantial (I2 = 72.4%). The sensitivity ofthe 10 studies was low, and the Begg and Egger tests did not
reveal publication bias. More details of sensitivity analysis
and publication bias assessment can be found in Supplemen-
tary Figs. S5 and S6.
Results of subgroup analyses on the effectiveness of differ-
ent types of interventions are presented in Fig. 4, Part A.
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ing the risk of DR progression (OR = 1.05; 95% CI 0.77 to 1.45;
P = 0.749), and there was no heterogeneity (I2 = 0.0%).
Glycemic-control intervention reduced the risk of DR progres-
sion significantly (OR = 0.71; 95% CI 0.52 to 0.97; P = 0.032), and
the heterogeneity was substantial (I2 = 81.6%). Lipid-control
intervention had no significant effect on reducing the risk of
DR progression (OR = 0.83; 95% CI 0.44 to 1.59; P = 0.581), and
the heterogeneity was substantial (I2 = 79.5%). Multifactorial
intervention reduced the risk of DR progression significantly
(OR = 0.39; 95% CI 0.23 to 0.65; P < 0.001), and there was no
heterogeneity among multifactorial intervention studies
(I2 = 0.0%).
Results of subgroup analyses on different follow-up inter-
vals are presented in Fig. 4, Part B. There was substantial
heterogeneity among interventions with follow-up of 2–
5 years (I2 = 66.4%). Interventions with follow-up of 2–5 years
reduced the risk of DR progression significantly (OR = 0.73;
95% CI 0.59 to 0.91; P = 0.006). There was substantial hetero-
geneity among interventions with follow-up of over 5 years
(I2 = 85.9%). Interventions with follow-up of over 5 years had
no significant effect on reducing the risk of DR progression
(OR = 0.84; 95% CI 0.39 to 1.80; P = 0.648).
4. Discussion
Our study found multifactorial intervention with individual-
ized target and communication between health professionals
and patients was more effective than other interventions in
the prevention and control of DR. Interventions with follow-
up of over 5 years had better effect on reduction of DR devel-
opment, and interventions with follow-up of 2–5 years and
over 5 years had better effect on reducing the risk of DR
worsening.
Our study showed that the effect of multifactorial inter-
vention on reducing the risk of DR development was superior
to that of blood-pressure-control intervention, glycemic-
control intervention or dietary-control intervention. A previ-
ous study on multifactorial intervention among patients with
type 2 diabetes also found that ‘‘intensive intervention with
multiple drug combinations and behavior modification had
sustained beneficial effects with respect to vascular complica-
tions and on rates of death from any cause and from cardio-
vascular causes” [26]. Apart from controlling multiple factors,
we also found that the similarities of the multifactorial inter-
ventions on prevention of DR in the subgroup analysis were
individualization and communication. Interventions and sup-
port for patients with type 2 diabetes were provided based on
patients’ situation [11,13,17]. For example, patients could get
recommendations on individualized goals to reach and could
attend age and gender-adjusted fitness programs [13]. More-
over, health professionals would communicate with patients
through education sessions, phones and emails [11,13,17].
Additionally, we found dietary-control intervention
(Mediterranean diet supplemented with olive oil or nuts) are
effective in preventing DR. A systematic review on dietary
intake and diabetic retinopathy also found that Mediter-
ranean diet, dietary fiber, fruits and vegetables, and oily-fish
have protective effect on DR [27]. However, both studies inour subgroup analysis of dietary-control intervention are
from the same article. The number of intervention studies
exploring the effect of dietary intake on DR is very limited
[20,27], thus more longitudinal studies in this field are
needed. According to our pooled results, controlling blood
pressure or blood glucose alone had no significant effect on
preventing DR among patients with type 2 diabetes. The find-
ing on blood glucose control is consistent with results from a
previous meta-analysis on the effects of intensive glycemic
control in ocular complications in patients with type 2 dia-
betes, which found no significant difference in the incidence
of retinopathy [1]. However, our finding on blood pressure is
different from the result of a review of 15 RCTs on blood pres-
sure stating that ‘‘the available evidence supports a beneficial
effect of intervention to reduce blood pressure with respect to
preventing diabetic retinopathy for up to 4 to 5 years” [28].
The possible reason of the differences might be that in our
study blood pressure control alone would be regarded as
blood-pressure-control intervention, while in that review arti-
cle, blood pressure control alone and blood pressure control
in combination with other interventions were all classified
as blood-pressure-control intervention. In addition, we only
included studies on patients with type 2 diabetes but the
review included patients with both type 1 and type 2 diabetes.
Regarding to the follow-up intervals, our results showed that
comparedwith interventionswith follow-up of 5 years or less,
interventions with follow-up of over 5 years had better effect
on preventing DR. A previous meta-analysis also had similar
result that ‘‘more intensive glucose control over 5 years
reduced both kidney and eye events” among patients with
type 2 diabetes [29].
Moreover, we explored the effect of interventions targeting
modifiable risk factors of DR on its worsening specifically,
which was rarely studied by previous meta-analysis studies.
We found blood-pressure-control intervention was effective
in slowing down DR worsening. However, controlling blood
glucose alone had no significant effect on the control of DR
worsening. A systematic review on DR also suggested that
there is no evidence that rapid improvement of blood glucose
control will reduce the risk of DR worsening [30]. As for
follow-up intervals, our results showed that compared with
interventions with follow-up of less than 2 years, interven-
tions with follow-up of 2–5 years and over 5 years had better
effect on reducing the risk of DR worsening. According to
the analysis on the follow-up intervals, the effect of interven-
tions on preventing DR can be observed after over 5 years,
while the effect on slowing down DR worsening can be
observed after 2 years, indicating that effect of interventions
on delaying DR worsening could be observed earlier than that
on preventing DR development.
Regarding DR progression (new onset or worsening), our
results indicated that multifactorial intervention also had
better effect on reduction of DR progression compared with
the blood-pressure-control intervention, glycemic-control
intervention and lipid-control intervention. Individualized
methods were adopted in the multifactorial intervention to
control the progression of DR [11,12,16]. For example, if
patients could not reach the blood pressure goal and/or blood
glucose goal set at the beginning after three months, stepwise
10 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 5 6 ( 2 0 1 9 ) 1 0 7 8 3 4approaches were adopted based on patients’ situation [12,16].
Additionally, we found glycemic-control intervention could
reduce the risk of DR progression, which is consistent with
previous meta-analysis [1,29]. The control of blood pressure
or lipid level alone had no significant effect on reduction of
DR progression among type 2 diabetes according to our
pooled results. A recent subgroup meta-analysis of 4 RCTs
found a borderline significant reduction in DR progression
with more intensive blood pressure lowering, which is differ-
ent from our finding [31]. However, they did not focus on dia-
betic patients and also reported substantial heterogeneity of
subgroup analysis. More studies on the effect of blood pres-
sure control on DR would be needed. As for follow-up inter-
vals, our results showed that compared with interventions
with follow-up of over 5 years, interventions with follow-up
of 2–5 years had better effect on reduction of DR progression.
However, the heterogeneity among interventions with follow-
up of over 5 years on DR progression was substantial. More
studies are still needed to verify this finding.
4.1. Strengths and limitations
This meta-analysis is the first to report variation among dif-
ferent intervention types targeting modifiable risk factors of
DR, and among different follow-up intervals of interventions
in patients with type 2 diabetes. However, the study still has
several limitations. First, no RCT included in our meta-
analysis was double-blinded study. Second, in subgroup anal-
yses, the number of studies in some subgroups (blood-
pressure-control intervention, dietary-control intervention
and lipid-control intervention) was small and there was a
high level of heterogeneity in some subgroups (the groups
of glycemic-control intervention and follow-up of over 5 years
for the analysis on effect on DR progression). One possible
reason of heterogeneity might be studies included in the
analyses of DR progression did not provide distinctive data
for new onset and worsening DR, and the variation between
studies might be large. Third, subgroup analyses on the influ-
ence of other factors (e.g. duration of diabetes, duration of DR,
intervention duration and frequency) could not be conducted
due to the limited number of studies. Fourth, our meta-
analysis has not been registered online.
4.2. Implications for practice and future researches
We found that multifactorial interventions can significantly
reduce the risk of developing DR and its progression among
patients with type 2 diabetes. More importantly, we found
all these multifactorial interventions contained individualiza-
tion of targets and communication between health profes-
sionals and patients, suggesting ophthalmologists and
diabetes health professionals should work together with
patients to set more individualized targets while taking into
account multiple factors so as to achieve optimal effect in
DR prevention and control. Training on interventions on DR
prevention and control should be carried out for general prac-
titioners in primary level health facilities so that they can
educate the patients with type 2 diabetes in this regard. In
the future, guidelines on how to perform better and more
effective DR prevention and control should be developed forgeneral practitioners. In addition, more studies on the effec-
tiveness of interventions targeting various modifiable risk
factors of DR in prevention and control of DR are needed.
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